Gold standard ANA detection
IFA on HEp-2/HEp-2010 substrate is considered the “gold standard” for primary ANA detection 1
Gold standard ANA detection
IFA on HEp-2/HEp-2010 substrate is considered the “gold standard” for primary ANA detection 1
Proprietary BIOCHIP technology
Allows for ANA detection on either HEp-2 or HEp-20-10 cell substrates, in a single miniature field
Unique HEp-20-10 Substrate
An increased number of mitotic cells enhances pattern interpretation and differentiation 3
Multiple testing platforms
ELISA, IFA, and EUROLINE immunoblots for flexible workflow integration
Connective tissue diseases (CTDs) are rheumatic diseases characterized by damage to the body’s connective tissues, including joints, muscles, skin, and internal organs. Autoantibodies against cellular components, including anti-nuclear antibodies (ANA), are important serological markers for CTD. Euroimmun delivers solutions to support ANA detection for efficient diagnosis of several CTD including:
Indirect immunofluorescence assay (IFA) on HEp-2 or HEp-20-10 cells remains the gold standard for ANA detection due to its high sensitivity and ability to reveal characteristic fluorescence patterns. The international consensus on ANA patterns (ICAP, www.anapatterns.org) defines nuclear, cytoplasmic, and mitotic patterns that guide clinical interpretation. 1,2
Euroimmun’s BIOCHIP technology allows for ANA detection on either HEp-2 or HEp-20-10 cells substrates, in a single miniature field. Unique to Euroimmun, the HEp-20-10 substrate provides a higher number of mitotic cells, aiding pattern interpretation and differentiation.3
Additionally, Euroimmun provides a range of solid-phase assays, including ELISA and EUROLINE immunoblots, covering autoantibodies relevant to SLE, SSc, SS, and myositis. These assays detect antibodies such as anti-dsDNA, anti-Sm, anti-SSA/SSB, anti-Scl-70, anti-centromere, anti-Jo-1, ribosomal P, and Ro-52.
References
For in vitro diagnostic use.
2026 Euroimmun US
Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap